Literature DB >> 19283722

CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets.

Christopher E Rudd1.   

Abstract

CTLA-4 has potent regulatory effects on the threshold of T-cell signalling and, in the process, guards against the development of hyper-proliferation and autoimmunity. Despite this, the role of CTLA-4 on specific T-cell subsets has been unclear. Such studies could shed light on both the function of CTLA-4, and on the contribution of the subsets to the disease phenotype of the Ctla4(-/-) mouse. Recently, a role for this co-receptor in the function of Treg has been outlined and, in this issue of the European Journal of Immunology, the selective targeting of the T-box transcription factor Eomes by CTLA-4 in the regulation of CD8(+) cytolytic T-cell (CTL) effector function is shown. Together, these papers shed light on the role of CTLA-4 in different T-cell subsets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19283722      PMCID: PMC3512132          DOI: 10.1002/eji.200939261

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  29 in total

1.  Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation.

Authors:  Naofumi Takemoto; Andrew M Intlekofer; John T Northrup; E John Wherry; Steven L Reiner
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 2.  The expansion and maintenance of antigen-selected CD8(+) T cell clones.

Authors:  Douglas T Fearon
Journal:  Adv Immunol       Date:  2007       Impact factor: 3.543

Review 3.  The reverse stop-signal model for CTLA4 function.

Authors:  Christopher E Rudd
Journal:  Nat Rev Immunol       Date:  2008-02       Impact factor: 53.106

4.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

5.  CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization.

Authors:  Helga Schneider; Xin Smith; Hebin Liu; Georges Bismuth; Christopher E Rudd
Journal:  Eur J Immunol       Date:  2008-01       Impact factor: 5.532

6.  CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin.

Authors:  Johannes K Hegel; Karin Knieke; Paula Kolar; Steven L Reiner; Monika C Brunner-Weinzierl
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

7.  Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.

Authors:  Emily M Schmidt; Chun Jing Wang; Gemma A Ryan; Louise E Clough; Omar S Qureshi; Margaret Goodall; Abul K Abbas; Arlene H Sharpe; David M Sansom; Lucy S K Walker
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

8.  CTLA-4 control over Foxp3+ regulatory T cell function.

Authors:  Kajsa Wing; Yasushi Onishi; Paz Prieto-Martin; Tomoyuki Yamaguchi; Makoto Miyara; Zoltan Fehervari; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2008-10-10       Impact factor: 47.728

9.  CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis.

Authors:  Anita L Tang; John R Teijaro; Modesta N Njau; Smita S Chandran; Agnes Azimzadeh; Steven G Nadler; David M Rothstein; Donna L Farber
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

10.  CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death.

Authors:  Helga Schneider; Elke Valk; Rufina Leung; Christopher E Rudd
Journal:  PLoS One       Date:  2008-12-04       Impact factor: 3.240

View more
  10 in total

1.  ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation.

Authors:  Nicholas A Zumwalde; Eisuke Domae; Matthew F Mescher; Yoji Shimizu
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

2.  Lin28b Regulates Fetal Regulatory T Cell Differentiation through Modulation of TGF-β Signaling.

Authors:  Yelena Bronevetsky; Trevor D Burt; Joseph M McCune
Journal:  J Immunol       Date:  2016-10-28       Impact factor: 5.422

3.  Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood.

Authors:  Xin Chen; Jeffrey J Subleski; Ryoko Hamano; O M Zack Howard; Robert H Wiltrout; Joost J Oppenheim
Journal:  Eur J Immunol       Date:  2010-04       Impact factor: 5.532

Review 4.  Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis.

Authors:  Sae Ohwada; Keisuke Ishigami; Noriyuki Akutsu; Hiroshi Nakase
Journal:  Biomedicines       Date:  2022-06-06

5.  Cytokine profile, proliferation and phosphorylation of ERK1/2 and Akt in circulating mononuclear cells from individuals during the chronic intestinal phase of Schistosomiasis mansoni infection.

Authors:  Roberta Oliveira-Prado; Iramaya Rodrigues Caldas; Andréa Teixeira-Carvalho; Marcus Vinicius Andrade; Rafaelle Christine Gomes Fares; Laís Maroni Portugal; Andréa Gazzinelli; Rodrigo Corrêa-Oliveira; José Renan Cunha-Melo
Journal:  BMC Infect Dis       Date:  2012-12-27       Impact factor: 3.090

6.  Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

Authors:  Wenshi Wang; Daohai Yu; Amod A Sarnaik; Bin Yu; Maclean Hall; Dawn Morelli; Yonghong Zhang; Xiuhua Zhao; Jeffrey S Weber
Journal:  J Transl Med       Date:  2012-07-12       Impact factor: 5.531

7.  Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans.

Authors:  Iwona Kwiecien; Anna Stelmaszczyk-Emmel; Malgorzata Polubiec-Kownacka; Dariusz Dziedzic; Joanna Domagala-Kulawik
Journal:  Cancer Immunol Immunother       Date:  2016-11-19       Impact factor: 6.968

Review 8.  Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.

Authors:  Ronald Anderson; Bernardo L Rapoport
Journal:  Front Oncol       Date:  2018-03-22       Impact factor: 6.244

9.  Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.

Authors:  Nourridine Siewe; Avner Friedman
Journal:  PLoS One       Date:  2022-01-11       Impact factor: 3.240

Review 10.  Immunotherapy as sensitizer for local radiotherapy.

Authors:  Ben G L Vanneste; Evert J Van Limbergen; Ludwig Dubois; Iryna V Samarska; L Wieten; M J B Aarts; T Marcelissen; Dirk De Ruysscher
Journal:  Oncoimmunology       Date:  2020-10-30       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.